nach oben

Erschienen in:

01.02.2016

A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy

verfasst von: J. A. Lawrence, L. Griffin, E. P. Balcueva, D. L. Groteluschen, T. A. Samuel, G. J. Lesser, M. J. Naughton, L. D. Case, E. G. Shaw, S. R. Rapp

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Some breast cancer survivors report cognitive difficulties greater than 1 year after chemotherapy. Acetylcholinesterase inhibitors (AChEI) may improve cognitive impairment. We conducted a randomized, placebo-controlled, pilot study to assess the feasibility of using the AChEI, donepezil, to improve subjective and objective measures of cognitive function in breast cancer survivors.

Methods

Women who received adjuvant chemotherapy 1–5 years prior with current cognitive dysfunction symptoms were randomized to 5 mg of donepezil/day vs placebo for 6 weeks and if tolerated 10 mg/day for 18 weeks for a total of 24 weeks. A battery of validated measures of attention, memory, language, visuomotor skills, processing speed, executive function, and motor dexterity and speed was administered at baseline and at 24 and 36 weeks. Subjective cognitive function, fatigue, sleep, mood, and health-related quality of life were evaluated at baseline and at 12, 24, and 36 weeks.

Results

Sixty-two patients were enrolled, 76 % completed the study, self-reported compliance was 98 %, and toxicities were minimal. At the end of treatment, the donepezil group performed significantly better than the control group on two parameters of memory—the Hopkins Verbal Learning Test -Revised (HVLT-R) Total Recall (p = 0.033) and HVLT-R Discrimination (p = 0.036). There were no significant differences on other cognitive variables or in subjective cognitive function or quality of life.

Conclusion

Accrual to this feasibility trial was robust, retention was good, compliance was excellent, and toxicities were minimal.

Implications for Cancer Survivors

Randomized clinical trials in breast cancer survivors to improve cognitive dysfunction are feasible. A phase III trial testing the efficacy of donepezil is warranted given these pilot results.

de Moor JS et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561–70.PubMedPubMedCentralCrossRef

Castellon SA et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955–69.PubMedCrossRef

Ahles TA et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.PubMedCrossRef

Kreukels BP et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8(1):80–7.PubMedCrossRef

Schagen SB et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50.PubMedCrossRef

Wefel JS et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9.PubMedCrossRef

Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000;15(7):603–30.PubMedCrossRef

Wefel JS et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.PubMedCrossRef

van Dam FS et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210–8.PubMedCrossRef

10.

Schagen SB et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98(23):1742–5.PubMedCrossRef

11.

Christie LA et al. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954–65.PubMedCrossRef

12.

Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev. 2008;18(2):121–31.PubMedCrossRef

13.

Koppelmans V et al. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol. 2015;33(6):588–93.PubMedCrossRef

14.

Silverman DH et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):303–11.PubMedCrossRef

15.

Inagaki M et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146–56.PubMedCrossRef

16.

Goldstein D et al. Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer. 2006;6:240.PubMedPubMedCentralCrossRef

17.

Jacobsen PB et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manag. 1999;18(4):233–42.CrossRef

18.

Jacobsen PB et al. Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer. 2007;110(8):1851–9.PubMedPubMedCentralCrossRef

19.

Broeckel JA et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16(5):1689–96.PubMed

20.

Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2003;(3):Cd001190, Review.

21.

Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol. 2004;7(3):351–69.PubMedCrossRef

22.

Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;(1):Cd004395, Review.

23.

Petersen RC et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42.PubMedCrossRef

24.

Ceravolo R et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol. 2004;27(4):166–70.PubMedCrossRef

25.

Shaw EG et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–20.PubMedCrossRef

26.

Rapp SR et al. Donepezil for irradiated brain tumor services: a phase III randomized, placebo-controlled clinical trial. J Clin Oncol. 2014;33(15):1653–9.CrossRef

27.

Vardy J et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8.PubMedCrossRef

28.

Brandt J. The Hopkins of Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neurophysiol. 1991;5(2):125–42.

29.

Saxton J, Becker JT, Wisniewski SR. The ROCF and dementia. In: Knight JA, Kaplan E, editors. The handbook of Rey–Osterrieth complex figure usage: clinical and research applications. Lutz, FL: Psychological Assessment Resources; 2003:659-82.

30.

Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6.CrossRef

31.

Ruff RM et al. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329–38.PubMedCrossRef

32.

Weschler D. Wechsler Adult Intelligence Scale-III (WAIS-III). New York: Psychological Corporation/Harcourt, Inc; 1996.

33.

Matthews CG, Klove H. Instruction manual for the adult neuropsychological test battery. Madison: University of Wisconsin Medical School; 1970.

34.

Wagner LI et al. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7(6):W32–9.

35.

Berger AM et al. Cancer-related fatigue. J Natl Compr Cancer Netw. 2010;8(8):904–31.

36.

Wagner LI et al. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J Clin Oncol. 2007;25(32):5058–62.PubMedCrossRef

37.

Cella D et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528–38.PubMedCrossRef

38.

Reeve BB et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 Suppl 1):S22–31.PubMedCrossRef

39.

Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540–5.PubMed

40.

Beck SL et al. Symptom experiences and quality of life of rural and urban older adult cancer survivors. Cancer Nurs. 2009;32(5):359–69.PubMedCrossRef

41.

Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ. 1993;2(3):217–27.PubMedCrossRef

42.

Mar Fan HG et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008;16(6):577–83.PubMedCrossRef

43.

Kohli S et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009;115(12):2605–16.PubMedPubMedCentralCrossRef

44.

Newhouse P et al. Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. Neuropsychopharmacology. 2013;38(13):2632–43.PubMedPubMedCentralCrossRef

45.

Bernstein LJ, Catton PA, Tannock IF. Intra-individual variability in women with breast cancer. J Int Neuropsychol Soc. 2014;20(4):380–90.PubMedCrossRef

46.

Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11(1):6–15.PubMedCrossRef

47.

Schagen SB et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13(9):1387–97.PubMedCrossRef

48.

Shilling V et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005;14(2):142–50.PubMedCrossRef

49.

Gross AL et al. Word list memory predicts everyday function and problem-solving in the elderly: results from the ACTIVE cognitive intervention trial. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2011;18(2):129–46.PubMedPubMedCentralCrossRef

50.

Hwang SY, Chang SJ, Park BW. Does chemotherapy really affect the quality of life of women with breast cancer? J Breast Cancer. 2013;16(2):229–35.PubMedPubMedCentralCrossRef

Titel: A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy
verfasst von: J. A. Lawrence
L. Griffin
E. P. Balcueva
D. L. Groteluschen
T. A. Samuel
G. J. Lesser
M. J. Naughton
L. D. Case
E. G. Shaw
S. R. Rapp
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 1/2016
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-015-0463-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy